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AbstrAct
ObjeCtive
To identify the number of drug-disease and drug-drug 
interactions for exemplar index conditions within 
National Institute of Health and Care Excellence (NICE) 
clinical guidelines.
Design
Systematic identification, quantification, and 
classification of potentially serious drug-disease and 
drug-drug interactions for drugs recommended by NICE 
clinical guidelines for type 2 diabetes, heart failure, 
and depression in relation to 11 other common 
conditions and drugs recommended by NICE 
guidelines for those conditions.
setting
NICE clinical guidelines for type 2 diabetes, heart 
failure, and depression.
Main OutCOMe Measures
Potentially serious drug-disease and drug-drug 
interactions.
results
Following recommendations for prescription in 12 
national clinical guidelines would result in several 
potentially serious drug interactions. There were 32 
potentially serious drug-disease interactions between 
drugs recommended in the guideline for type 2 diabetes 
and the 11 other conditions compared with six for drugs 
recommended in the guideline for depression and 10 for 
drugs recommended in the guideline for heart failure. Of 
these drug-disease interactions, 27 (84%) in the type 2 
diabetes guideline and all of those in the two other 
guidelines were between the recommended drug and 
chronic kidney disease. More potentially serious 
drug-drug interactions were identified between drugs 
recommended by guidelines for each of the three index 
conditions and drugs recommended by the guidelines 
for the 11 other conditions: 133 drug-drug interactions 
for drugs recommended in the type 2 diabetes 
guideline, 89 for depression, and 111 for heart failure. 
Few of these drug-disease or drug-drug interactions 
were highlighted in the guidelines for the three index 
conditions.
COnClusiOns
Drug-disease interactions were relatively uncommon 
with the exception of interactions when a patient also 
has chronic kidney disease. Guideline developers could 
consider a more systematic approach regarding the 
potential for drug-disease interactions, based on 
epidemiological knowledge of the comorbidities of 
people with the disease the guideline is focused on, 
and should particularly consider whether chronic kidney 
disease is common in the target population. In contrast, 
potentially serious drug-drug interactions between 
recommended drugs for different conditions were 
common. The extensive number of potentially serious 
interactions requires innovative interactive approaches 
to the production and dissemination of guidelines to 
allow clinicians and patients with multimorbidity to 
make informed decisions about drug selection.
Introduction
Despite widespread multimorbidity, clinical guidelines 
are largely written as though patients have a single condi-
tion and the cumulative impact of treatment recommen-
dations from multiple clinical guidelines is not generally 
considered.1 2 In people with several conditions, simply 
application of recommendations from multiple single dis-
ease clinical guidelines can result in complex multiple 
drug regimens (polypharmacy) with the potential for 
implicitly harmful combinations of drugs.3–5 Clinical 
guidelines of course are not intended to be completely 
comprehensive guides to practice, in that clinicians are 
expected to use their judgment in deciding which treat-
ments are appropriate in individual patients. There is, 
however, increasing recognition that clinical guidelines 
should better account for patients with multimorbidity.2 6
Adverse drug events cause an estimated 6.5% of 
unplanned hospital admissions in the United Kingdom, 
WhAt Is AlreAdy knoWn on thIs topIc
There is increasing recognition that clinical guidelines should better account for 
patients with multimorbidity
Many guidelines recommend drug treatments, but current guidelines rarely 
consider drug-disease or drug-drug interactions in these recommendations
WhAt thIs study Adds
For the 12 guidelines examined, drug-disease interactions were relatively 
uncommon, with the exception of interactions when an individual has comorbid 
chronic kidney disease
Potentially serious drug-drug interactions were common, although the harm caused 
will depend on both how commonly different conditions are comorbid and the 
prevalence and severity of the harm caused by the interaction
Guideline developers need to more explicitly account for drug-disease and 
drug-drug interactions in people with multimorbidity and should use 
epidemiological evidence to identify when interactions are likely to be common and 
serious enough to require specific mention in a guideline.
Guideline developers are currently limited by the use of paper based guidelines. 
Adaptive electronic based guidelines that allow interactive searching for specific 
conditions are a potential way forward to account for multimorbidity in guideline 
recommendations
 open access
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accounting for 4% of hospital bed capacity.7 When an 
admission ends in death, these are predominately the 
result of bleeding or renal injury.7 While some adverse 
drug events are unpredictable (such as anaphylaxis from 
an unrecognised allergy), many others can be predicted 
and prevented, including drug-disease and drug-drug 
interactions.8 A considerable proportion of adverse drug 
events are caused by interactions between drugs.9 Sys-
tematic reviews have shown that electronic alerts and 
prompts can improve prescribing behaviour or reduce 
rates of error.10 Nevertheless, despite the increasing avail-
ability of computerised decision support, adverse drug 
events as a cause for seeking ambulatory care have 
increased, nearly doubling in the United States between 
1995 and 2005, with increasing age and increasing poly-
pharmacy being the predominant characteristics of 
patients associated with experiencing such an event.4 
With an ageing population, and associated increasing 
multimorbidity, there is an increase in the potentially 
required number of drugs11 and so the potential for 
increased risk of drug interactions.8 12 The American Geri-
atrics Society has identified the consideration of drug-dis-
ease and drug-drug interactions as a key element of 
optimal care for older adults with multimorbidity.13
We quantified how often the drugs recommended by 
three exemplar clinical guidelines from the National 
Institute of Health and Care Excellence (NICE) have 
drug-disease interactions in the presence of other com-
monly comorbid conditions or have potentially serious 
drug-drug interactions with drugs recommended by 
guidelines for these conditions.
Methods
We selected three exemplar clinical guidelines pro-
duced by NICE, chosen because they were for common 
and important chronic physical and mental health con-
ditions: heart failure,14 type 2 diabetes,15 and depres-
sion.16 Nine other NICE guidelines for potentially 
comorbid conditions were then selected. Guidelines 
were chosen on the basis of being a common and 
chronic condition; being recently published; including 
recommendations for the initiation of a drug treatment 
for a chronic condition, and being for conditions com-
monly comorbid with the three index conditions (fig 1). 
These nine conditions were atrial fibrillation,17 osteoar-
thritis,18 chronic obstructive pulmonary disease 
(COPD),19 hypertension,20 secondary prevention after 
myocardial infarction (post-myocardial infarction),21 
dementia,22 rheumatoid arthritis,23 chronic kidney dis-
ease,24 and neuropathic pain.25
For each of the 12 guidelines, a panel of three clini-
cians (a general practitioner and two pharmacists) 
reviewed all recommendations made regarding the initi-
ation of chronic drug treatments. We defined a drug as 
“first line” if it was recommended as a treatment for all or 
nearly all people with the condition, (for example angio-
tensin converting enzyme inhibitors for people with 
heart failure), whereas drugs that were recommended for 
only some patients with the condition under some cir-
cumstances were defined as “second line” (for example 
spironolactone for people with heart failure and high 
levels of symptoms despite first line treatment).
The expert panel then identified and classified 
drug-disease and drug-drug interactions and exam-
ined published guidelines to see if identified interac-
tions were explicitly discussed. The British National 
Formulary (BNF) is the primary source used by UK 
 clinicians to obtain information on drug-drug and 
drug-disease interactions.26 For each of the three 
exemplar index guidelines we systematically searched 
the BNF to identify drug-disease warnings for guide-
line recommended drugs, taking account of the pre-
defined 11 conditions (the other two index conditions 
and the nine others). Drug-disease warnings were 
defined as being important if a disease was stated to 
be a contraindication in relation to all or most people 
with the condition, or if the BNF stated that drugs 
should be used only with caution accompanied by a 
clear statement to avoid in all or most people with the 
condition. For chronic kidney disease but not for other 
conditions, BNF warnings often recommended dose 
adjustment, and therefore this was additionally 
counted for this condition.
The BNF categorises drug-drug interactions by sever-
ity and defines potentially serious interactions as ones 
when “concomitant administration of the drugs 
involved should be avoided (or only undertaken with 
caution and appropriate monitoring).”26 Of note is that 
the “potentially serious” designation is not an indica-
tion of the likelihood of an interaction but of the seri-
ousness of the potential harm if it occurs. The expert 
panel used the BNF to identify potentially serious inter-
actions between drugs recommended by each of the 
three index guidelines and drugs recommended by any 
of the 12 guidelines (as two drugs recommended in the 
same guideline can interact). The expert panel then 
classified each identified drug-drug interaction in terms 
of the type of potential adverse effect caused. Disagree-
ment between panel members was resolved by discus-
sion to reach a consensus view. The potential harms 
of  included interventions were then classified into 
risk  of bleeding; central nervous system toxicity; 
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Fig 1 | Proportion of people with three index conditions who have each of other conditions. 
Morbidity data were not available for osteoarthritis or neuropathic pain; “painful 
condition” data shown are defined by receipt of four or more prescriptions for non-over 
the counter analgesics in previous 12 months
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 cardiovascular adverse effect  (including change in 
blood pressure or effect on heart rate or rhythm); and 
effect on renal function or serum potassium, or other. 
The “other” classification included risk associated with 
changes in concentration of drugs with a narrow thera-
peutic index such as lithium carbonate, digoxin, and 
theophylline.27 We chose these classification categories 
to reflect the types of adverse drug events associated 
with emergency admission to hospital.7
results
Table 1 shows the number of drugs or drug classes recom-
mended as first line (for all or nearly all patients) and sec-
ond line (for some patients under some circumstances) 
for each condition (details of the individual drugs are in 
appendix 1). There were 23 drugs recommended in the 
type 2 diabetes guideline (four first line), 13 drugs in the 
depression guideline (one first line), and 11 in the heart 
failure guideline (two first line).
Drug-disease interactions
Table 2 shows the number of times that a drug recom-
mended for each of the three index conditions would be 
contraindicated or should be avoided in the presence of 
any of the other 11 conditions. Drug-disease interactions 
were not common, with the exception of those related to 
chronic kidney disease, which occurred with type 2 diabe-
tes in particular. Chronic kidney disease was involved in 
27 of the identified 32 drug-disease interactions for drugs 
recommended in the clinical guideline for type 2 diabetes 
and all of the six and 10 drug-disease interactions for the 
guidelines for depression and heart failure, respectively. 
But the guidelines for type 2 diabetes and heart failure 
each specifically discussed just one of these identified 
interactions. For type 2 diabetes this recommendation 
was regarding the need to avoid treatment with thiazoli-
dinediones in people with comorbid heart failure. In 
heart failure, it was identified that amlodipine should be 
considered for the treatment of comorbid hypertension 
and/or angina in patients with heart failure, but ver-
apamil, diltiazem, or short acting dihydropyridine agents 
should be avoided. The depression guideline did not dis-
cuss any of the identified drug-disease interactions.
Drug-drug interactions
Potentially serious drug-drug interactions were common 
(fig 2). We identified 133 potentially serious interaction 
pairs for the type 2 diabetes guideline, of which 25 (19%) 
involved one of the four drugs recommended as first line 
treatments for all or nearly all patients (appendix 1). 
Nine of the recommended drugs for diabetes did not 
have any drug-drug interactions. For the depression 
guideline, we identified 89 potentially serious drug-drug 
interaction pairs, of which 19 (21%) involved the one 
drug class recommended as first line (selective serotonin 
reuptake inhibitor antidepressants). For heart failure, 
there were 111 potentially serious drug-drug interaction 
pairs identified, of which 21 (19%) involved the two drug 
classes recommended as first line.
table 1 | number of drugs recommended for each condition in each niCe guideline 
considered
Condition guideline no Year published
no of drugs/drug classes 
recommended
First line second line
Type 2 diabetes CG87 2009 4 19
Depression CG90 2009 1 12
Heart failure CG108 2010 2 9
Atrial fibrillation CG36 2006 4 7
Dementia CG42 2006 3 1
Secondary prevention post-MI CG48 2007 4 13
Osteoarthritis CG59 2008 2 5
Chronic kidney disease CG73 2008 1 6
Rheumatoid arthritis CG79 2009 9 9
Neuropathic pain CG96 2010 2 5
Chronic obstructive pulmonary 
disease
CG101 2010 2 8
Hypertension CG127 2011 4 3
NICE=National Institute of Health and Care Excellence; MI=myocardial infarction.
table 2 | number of drug-disease interactions between drugs/drug classes recommended for each index condition and 11 other conditions in niCe 
guidelines. First line treatments are explicitly described as first line drugs or recommended for (almost) everyone with the condition; second line 
treatments (or other drugs) are explicitly described as second or third line drugs or recommended for only some subgroups or in some uncommon 
circumstances
index 
conditions
CKD (dose 
change)
CKD 
(avoid)
Heart 
failure Depression
type 2 
diabetes
atrial 
fibrillation Osteoarthritis COPD Hypertension
Post 
Mi Dementia
rheumatoid 
arthritis
neuropathic 
pain total
type 2 diabetes*
First line 3 2 0 0 — 0 0 0 0 0 0 0 0 5
Second line 11 11 5 0 — 0 0 0 0 0 0 0 0 27
Depression†
First line 1 0 0 — 0 0 0 0 0 0 0 0 0 1
Second line 2 3 0 — 0 0 0 0 0 0 0 0 0 5
Heart failure‡
First line 2 1 — 0 0 0 0 0 0 0 0 0 0 3
Second line 3 4 — 0 0 0 0 0 0 0 0 0 0 7
*CG87 type 2 diabetes: first line: metformin, sulphonylurea, angiotensin converting enzyme inhibitors (ACEI), simvastatin/atorvastatin. Second line/other: angiotensin II receptor antagonists 
(ARB) for hypertension, calcium channel blocker for hypertension, diuretic for hypertension, α blocker for hypertension, β blocker for hypertension, K-sparing diuretic for hypertension, other 
statins (not simvastatin/atorvastatin), fibrate, erythromycin, phosphodiesterase type-5 inhibitors (PPDE5 inhibitors), metoclopramide, ezetemibe, omega-3 fish oil, domperidone, DPP-4 
inhibitor/gliptin, thiazolidinedione, GLP-1 mimetic (exenatide), acarbose, insulin.
†CG90 depression: first line: selective serotonin reuptake inhibitors. Second line: venlafaxine, mirtazepine, duloxetine, reboxetine, flupenthixol, tryptophan, mianserin, tricyclic antidepressant 
(TCA), monoamine oxidase inhibitor (MAOI), moclobemide, lithium, antipsychotic (aripiprazole, olanzapine, quetiapine, risperidone).
‡CG108 heart failure: first line: ACEI, β blocker licensed for heart failure. Second line/other: licensed aldosterone antagonist, digoxin, ARB, hydralazine, nitrate, loop diuretic, warfarin, 
amlodipine if comorbid hypertension/angina, aspirin if comorbid coronary heart disease.
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Figure 3 illustrates and Table 3 summarises the types 
of harm expected from potentially serious drug-drug 
interactions by index condition (see appendix 2 for fur-
ther detail). For type 2 diabetes, the most common cate-
gory was cardiovascular related harm such as significant 
hypotension or bradycardia, followed by “other” (which 
includes increased lithium or digoxin concentrations 
causing risk of toxicity, and myopathy with statin treat-
ment), and renal or serum potassium associated harms. 
For depression, the most commonly identified harm was 
risk of bleeding, particularly with selective serotonin 
reuptake inhibitors recommended as first line, followed 
by “other” harms (most commonly relating to lithium 
toxicity), and cardiovascular and central nervous system 
toxicity. Most of cardiovascular adverse effects in the 
depression guideline were related to increased risk of 
ventricular arrhythmias. The most common potentially 
serious drug interactions for the heart failure guideline 
were for bleeding events, but interactions causing severe 
hypotension or related to increased digoxin or lithium 
concentrations causing risk of toxicity were also cited.
A limited number of the identified drug-drug interac-
tions were highlighted in the guidelines for the index 
condition. In the guideline for type 2 diabetes, only two 
interactions were mentioned: potassium sparing diuret-
ics with angiotensin converting enzyme inhibitors; and 
potassium sparing diuretics with angiotensin receptor 
blockers. The depression guideline highlighted only the 
increased risk of bleeding with selective serotonin 
reuptake inhibitors plus non-steroidal anti-inflamma-
tory drugs or aspirin. None of the recommendations in 
the heart failure guideline contained an explicit discus-
sion of the 111 potentially serious drug-drug interac-
tions identified.
discussion
Principle findings
In this review of NICE clinical guidelines, potentially 
serious drug-drug interactions were relatively common 
among recommendations for each of three index con-
ditions (type 2 diabetes, heart failure, and depression) 
and 11 other common conditions. In contrast, drug-dis-
ease interactions were relatively uncommon except in 
patients with comorbid chronic kidney disease. The 
types of harm potentially introduced by co-prescrip-
tion of drugs varied by clinical guideline and were most 
commonly related to cardiovascular and “other” for 
drugs recommended for diabetes; bleeding and “other” 
for depression; and bleeding and cardiovascular for 
heart failure. Many guidelines suggest starting a drug 
treatment but currently rarely seem to consider 
drug-disease or drug-drug interactions in their recom-
mendations.
Comparison with other studies
Previous studies of the implications of following single 
disease guidelines in people with multimorbidity have 
usually considered single hypothetical patients with 
carefully selected multiple conditions; a scenario that 
is likely to overstate the scale of the problem.5 28 Using 
US population survey data, Lorgunpai and colleagues 
found a much higher rate of drug-disease interactions 
(which they termed “therapeutic competition”), with a 
fifth of older American adults being prescribed drugs 
for one condition with the potential to worsen 
another.29 Their study, however, included interactions 
that did not reach our threshold of being recommended 
to avoid in all or most patients (for example, the use of 
β blockers for coronary heart disease in people with 
chronic obstructive pulmonary disease was common in 
their study but, although it carries some risk, is not 
stated as a contraindication or recommendation to 
avoid in the BNF because the benefits outweigh the 
harms in most patients).
strengths and limitations of study
One key potential limitation is the use of a selection of 
clinical guidelines as exemplar case studies, and some 
other guidelines do discuss interactions in more 
detail. For example, NICE has produced a guideline for 
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Fig 2 | Potentially serious drug-drug interactions between drugs recommended by clinical guidelines for three index 
conditions and drugs recommended by each of other 11 other guidelines
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 depression in people with a chronic physical health 
problem30 that includes extensive discussion about drug 
interactions (although in a full guideline appendix, 
which will not be commonly read by clinicians) and a 
guideline on management of bipolar disorder31 that 
includes detailed recommendations about safe use of 
lithium. We would not, however, expect the pattern of 
findings to be substantially different for other guidelines 
that include a reasonable number of recommendations 
for chronic drug treatment. We excluded from our analy-
sis any recommendations for starting drugs for acute 
conditions, but it should be noted that interactions with 
drugs like antibiotics and non-steroidal anti-inflamma-
tory drugs (NSAIDs) used for short term intercurrent ill-
ness are common and important.3 The inclusion of 
additional guidelines would have further increased the 
number of potential interactions identified. Both of these 
exclusions imply that our findings are likely to be conser-
vative.
We systematically examined recent national guide-
lines produced by NICE for important and common 
clinical conditions using data on interactions drawn 
from a single authoritative UK source. Definition of 
contraindications and potentially serious interactions 
was not straightforward, reflecting that the risk of such 
events is often poorly quantified and information 
sources vary in what is rated to be important.32 We used 
the BNF because it is the reference source used by most 
UK based clinicians. The BNF draws on data from a 
manufacturer’s summary of product characteristics 
(SPC), the medical literature, and expert opinion, but 
other reference sources might not be consistent with 
this, and databases of listed potentially serious drug 
interactions might have yielded different results. For 
example, a summary of product characteristics for ami-
triptyline from the online electronic medicines com-
pendium of up to date, approved, and regulated 
prescribing information for licensed medicines33 
includes history of myocardial infarction as a contrain-
dication but the BNF 66th edition states only contrain-
dication in the immediate recovery period after 
myocardial infarction.
Conclusions and policy implications
We recommend that during the development of clinical 
guidelines the process should consider how to identify 
and more explicitly highlight the potential for interac-
tions between recommended drugs and other condi-
tions and other drugs that patients with the guideline 
condition are likely to have.34 35 It is important to 
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Fig 3 | types of potentially serious harm from drug-drug interactions between drugs recommended by clinical guidelines 
for three index conditions and drugs recommended by each of other 11 other guidelines
table 3 | type of harm expected from potentially serious drug-drug interaction for each index condition
index condition Cardiovascular* bleeding renal/potassium Central nervous system Other† total
type 2 diabetes
First line recommended drug 3 3 2 0 12 20
Second line recommended drug 54 11 18 1 29 113
Depression
First line recommended drug 1 9 0 7 2 19
Second line recommended drug 10 13 0 27 20 70
Heart failure
First line recommended drug 15 0 4 0 2 21
Second line recommended drug 17 34 17 0 22 90
*Includes effects on heart rate or rhythm or effects on blood pressure.
†Includes myopathy with statin treatment, or clinically relevant altered plasma concentration (for example, of digoxin, lithium, ciclosporin, or 
theophylline), which might require dose alteration or closer monitoring.
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acknowledge that guideline developers have to maintain 
a balance between producing clear and relatively short 
recommendations and avoiding glossing over the com-
plexity of the real world.36
For the conditions examined in our study, major 
drug-disease interactions were relatively rare with the 
exception of chronic kidney disease when interactions 
were more common. An implication is therefore that 
guideline developers should always explicitly decide 
whether chronic kidney disease is common enough in 
the real world population with the disease under consid-
eration to require comment or modification of recom-
mendations. For the three index conditions we 
examined, prevalence of comorbidity with chronic kid-
ney disease was about 4% in patients with depression, 
14% in patients with type 2 diabetes, and 23% in patients 
with heart failure. So the implication might be that 
guideline developers should consider chronic kidney 
disease with heart failure, possibly consider it with type 
2 diabetes, and possibly not consider it with depression.
Potentially serious drug-drug interactions were 
much more common, but there are too many for all of 
them to be specifically mentioned by guidelines. From 
this perspective, we suggest that clinical guidelines 
produced and disseminated in a paper based format 
will only ever be able to adequately account for a 
minority of potential drug-drug interactions. Guideline 
developers should acknowledge potentially serious 
interactions and estimate their likely prevalence and 
severity. Prevalence will be determined both by whether 
the drug being recommended is first line (intended for 
all or nearly all people with the condition), by how com-
monly interacting drugs are used, which will depend on 
rates of comorbidity, and by how often the adverse drug 
event in question occurs. Of note is the requirement for 
detailed information about the real world population 
that the guideline is making recommendations for, 
which is currently much less commonly used in guide-
line development than trial data from narrowly selected 
populations. With the growth of large electronic pri-
mary care datasets, there is the option to define the pop-
ulation for which recommendations are being made 
and describe its demography, comorbidity, and current 
prescribing. As an example, there is a potentially seri-
ous interaction between statins recommended as first 
line treatment for patients with type 2 diabetes and cic-
losporin recommended as second line for those with 
rheumatoid arthritis because of the risk of myopathy 
(and rhabdomyolysis). Given that only 1.4% of people 
with type 2 diabetes also have rheumatoid arthritis and 
that ciclosporin is recommended as second line only for 
those with rheumatoid arthritis, this will only ever be a 
rare drug-drug interaction and so is unlikely to reach 
the threshold for explicit consideration by a guideline 
development group. In contrast, co-prescription of 
selective serotonin reuptake inhibitors (recommended 
as first line treatment for patients with depression) and 
tramadol (recommended as second line for painful con-
ditions) is likely to be common because tramadol is 
commonly used for pain in the UK and over 27% of peo-
ple with depression also have painful conditions.1 37 
Although serotonin syndrome is potentially fatal, the 
risk of this condition seems to be low, but it is poorly 
quantified.38 The guideline development group will 
have to make a judgment as to whether they believe the 
interaction requires specific mention to inform clini-
cians and patients to be aware of the signs and symp-
toms of this syndrome should they occur. The key issue 
is that interactions and risks should be systematically 
assessed and explicit decisions made about whether 
they require discussion in a guideline, similar to the 
requirement for treatment benefits to be systematically 
and explicitly assessed. Details of expected harm from 
the identified potentially serious drug-drug interactions 
(such as those in appendix 2) should be considered to 
inform clinicians about alternative drug choices or to 
inform their discussions with individual patients.
Boxes 1 and 2 provide two illustrations of this. Box 1 
describes a fairly simple set of drug-drug interactions in 
a woman with new diagnosis of depression after a myo-
cardial infarction (in previous work, we found that 15% 
of people with a history of myocardial infarction have 
recent depression or are receiving antidepressants).39 
bOx 1—a new DiagnOsis OF DePressiOn
A 63 year old woman attends a GP appointment with her husband for follow-up of a 
new diagnosis of depression. She has had no benefit from low intensity 
psychosocial intervention and would like to discuss prescription for an 
antidepressant.
Medical history
Recent acute myocardial infarction (three months ago) and a history of 
hypertension. She struggles with increasing weight, which exacerbates flare up of 
pain from osteoarthritis in her knees. Current BMI is 32 and blood pressure 
152/82 mm Hg at last check, eGFR >60 ml/min/1.73 m2.
Current drug treatment
Aspirin 75 mg daily, clopidogrel 75 mg daily, atorvastatin 40 mg daily, ramipril 5mg 
twice daily, atenolol 50 mg daily, paracetamol 500 mg as required. While discussing 
her drugs she explained that she also buys occasional ibuprofen when required for 
her knee pain because her prescribed paracetamol does not always relieve her 
pain.
Considerations for depression management
Selective serotonin reuptake inhibitors are recommended as the first line choice of 
antidepressant by the NICE guideline, but there are potentially serious drug 
interactions between selective serotonin reuptake inhibitors, aspirin, clopidogrel, 
and the ibuprofen the patient buys over the counter. Some alternative 
antidepressants including mirtazapine, duloxetine, and reboxetine do not have this 
interaction, although venlafaxine does.
Outcome
•	After discussion with the patient a prescription for mirtazapine was started, and 
follow-up organised
•	Regarding her knee pain and to reduce her risk of gastrointestinal bleeding, 
support was also organised for exercise and diet and co-codamol (paracetamol 
500 mg/codeine 15 mg) was added as required for pain with caution regarding 
constipation and recommendation that she does not take ibuprofen
•	She was offered a proton pump inhibitor for gastroprotection while taking dual 
antiplatelet therapy but declined as she was still coming to terms with having to 
take five drugs for cardiovascular secondary prevention.
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The key issue is that selective serotonin reuptake inhib-
itors increase the risk of bleeding for someone already 
taking antiplatelet drugs (in this case dual treatment 
with aspirin and clopidogrel), and this issue is explic-
itly covered by NICE guidance.30
Box 2 describes a more complex situation in a 72 
year old man with a new diagnosis of type 2 diabetes 
who has pre-existing heart failure, atrial fibrillation, 
and chronic kidney disease (8.9% of people aged 
70–79 with type 2 diabetes have heart failure, 9.4% 
have atrial fibrillation, and 10.4% have chronic kidney 
disease).39 Here treatment choices are more con-
strained in the face of multiple drug-drug and 
drug-disease interactions, and effective diabetes treat-
ment might require more global treatment optimisa-
tion. In both cases, clinician judgment and patient 
involvement will be needed to make treatment deci-
sions, but current guideline recommendations do not 
always support this process.
One of the challenges for guideline developers is that 
the actual harms of many drug-drug and drug-disease 
interactions are poorly quantified, partly reflecting that 
whereas clinical trials produce high quality evidence 
about benefit, they are poorly suited to estimating 
harms, particularly in real world populations in which 
people are typically older, frailer, have more multiple 
illnesses. and prescribed more drugs for other condi-
tions than trial populations.40 Research is needed to 
more systematically quantify these harms because 
understanding when harms outweigh benefits is critical 
for rational treatment decisions, and better under-
standings of harm and the implications for the extrapo-
lation of trial findings to real world populations will 
need to be systematically incorporated into existing 
guideline development frameworks like GRADE.41 Paper 
based single disease guidelines are intrinsically limited 
by being hard to integrate for people with multiple con-
ditions and by being unable, for reasons of length and 
usability, to document all possible interactions. In prin-
ciple, guidelines embedded in electronic medical 
records that integrate recommendations for all the con-
ditions an individual has could deal with the problem 
we identified, including the difficulty of accounting for 
high levels of complexity such as the patient described 
in box 2, but the best design and effectiveness of such 
guidelines requires more research.42
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bOx 2—a new DiagnOsis OF tYPe 2 Diabetes
A 72 year old man attends with his wife for follow-up by his general practitioner 
regarding a new diagnosis of type 2 diabetes. He has not managed to control HbA1C 
with a trial of lifestyle interventions, despite strictly adhering to diet. Examination 
showed mild ankle oedema. Short of breath after about half flight stairs. Results show 
HbA1c 60 mmol/mol (normal range 31–44 mmol/mol, equivalent to HbaA1c 8% 
normal range 5.0–6.2%) BMI 24, blood pressure 102/68 mm Hg, pulse 50 beats/min.
Medical history
He has longstanding hypertension and atrial fibrillation. He was investigated for 
increased shortness of breath two years ago and found to have moderate left 
ventricular systolic dysfunction. He has chronic kidney disease with a most recent 
eGFR of 37 ml/min/1.73 m2 (previously fluctuating between 34 and 39) and 
creatinine 129 µmol/L (normal range 50–120 µmol/L).
Current drug treatment
Ramipril 2.5 mg daily, spironolactone 25 mg daily, bisoprolol 5 mg daily, 
simvastatin 40 mg daily, amlodopine 5 mg daily, furosemide 40 mg daily, warfarin 
as per international normalised ratio.
Considerations for management of type 2 diabetes 
NICE guidelines recommend several lifestyle and pharmacological interventions:
•	Continuation of lifestyle measures for management of diabetes 
•	Management of cardiovascular risk 
•	Pharmacological interventions are already in place to manage his lipids and 
blood pressure, and he is a non-smoker
•	Management of hyperglycaemia:
Metformin can be used with caution in renal function, review dose if eGFR 
<45 ml/min/1.73 m2, and avoid if eGFR <30 ml/min/1.73 m2
Option to start metformin with close monitoring of renal function
Sulphonylureas have a potentially serious drug interaction with warfarin, 
causing changes to anticoagulant effect and enhanced hypoglycaemic effect
Option to start sulphonylurea and close monitoring of international normalised 
ratio or
Option to start sulphonylurea and change warfarin to a newer anticoagulant 
such as rivaroxaban
Pioglitazone is contraindicated with heart failure.
•	Also potentially serious interaction between amlodipine and simvastatin with 
increased risk of myopathy (the amlodipine might also be contributing to the 
ankle oedema)
Outcome
•	Discussed diabetic control in context of other conditions. Patient chose to start 
metformin to help manage hyperglycaemia
•	He was concerned about instability in his international normalised ratio. He 
would also like to consider change from warfarin to rivaroxaban at some point in 
the future but is reluctant to start too many new drugs at once
•	Stop amlodipine (as it might be contributing to ankle swelling and his blood 
pressure is currently well controlled) and monitor blood pressure. Also the drug 
interaction would require a review of the statin therapy
•	Blood pressure might recover enough to allow increased dose of ramipril, which 
will help nephropathy and heart failure (renal function permitting)
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Appendix 1: First and second line drugs recom-
mended in 12 selected NICE Clinical Guidelines [posted 
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